News and Press Releases

Contact Veristat Now


Request A Proposal

Contact Us

Veristat Congratulates Origin Biosciences for FDA Approval

Veristat Congratulates Origin Biosciences for FDA Approval of Nulibry during the Week of Rare Disease Day 2021


Veristat Supported the NDA and Celebrates this Milestone Achievement for Children and their Families Fighting This Rare Disease



SOUTHBOROUGH, MA – 8 March 2021 –Veristat, a scientific-minded, global clinical research organization (CRO), today congratulated Origin Biosciences for their FDA approval of Nulibry (fosdenopterin) for injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A. This rare disease product received FDA approval on Friday, 26 February 2021, during the week when the world celebrated #RareDiseaseDay2021.

Read More

Veristat Launches Business Operations in Spain and Names Dr. Montserrat Barceló to Vice President, Europe

Leading the Organic and Acquisition Growth of Veristat Operations Throughout Europe

 

Read More

Veristat Named a Top Patient Recruitment Company by PharmaTech Outlook

Delivering A Patient-Centric Approach to Recruitment and Retention for Clinical Trials

SOUTHBOROUGH, MA – December 7, 2020 –Veristat, a global clinical research organization, was named among the Top Patient Recruitment Companies of 2020 by Pharma Tech Outlook.

Read More

Veristat Announces Global Cell and Gene Therapy Center of Excellence

Accelerating cell and gene therapy opportunities for patients by advancing access to knowledge and leveraging experience for sponsors to increase program success

SOUTHBOROUGH, MA – October 22, 2020 – Cell and gene therapies represent the next great wave of therapeutic innovation and have led to the development of promising therapies worldwide.

Read More

Veristat Launches A Flexible Virtual Clinical Trial Solution

Veristat Enhances Patient-Centricity Offering by Delivering Clinical Trials
Directly to Patients

SOUTHBOROUGH, MA – September 30, 2020 – Veristat, a scientific-minded global clinical research organization (CRO), announced today the launch of a virtual clinical trial solution that is flexible and customizable so that patient interactions can be conducted at the clinical site, remotely at-home, or through a hybrid combination of both strategies.

Read More

Veristat Helps Antibe Therapeutics Complete Their Phase IIB Study During COVID-19

In early 2019, Veristat helped Antibe Therapeutics, a biotech company with a drug platform of game-changing therapeutics in pain and inflammation, initiate the second part of their phase 2B dose-ranging, efficacy study for ATB-346. To date, this is one of the largest studies completed in Canada consisting of 360 patients with osteoarthritis (“OA”) of the knee, across 40 clinical sites.   

Read More

Veristat Strengthens Its European Presence with the Acquisition of TCTC

Increasing Its Footprint and Expanding Therapeutic Expertise to Guide Sponsors Throughout the Clinical Development Lifecycle

Read More

Veristat Advances Game-Changing Pain and Inflammation Therapy

Veristat continues to support Antibe Therapeutics, a biotech company with a drug platform of game-changing therapeutics in pain and inflammation, as they receive approval to initiate the second part of their phase 2B dose-ranging, efficacy study for ATB-346. 

Read More

Veristat Supports 12% of all FDA NME Approvals in 2018, a Record-Setting Year for FDA Approvals

Veristat Celebrates Its Support of over 75 Global Regulatory Submissions Since Its Founding

 

Read More

Veristat Supports Antibe Therapeutics for Pain and Inflammation Study

Upon receiving approval from Health Canada, Antibe Therapeutics selected Veristat to immediately begin work on part one of a Phase 2B dose-ranging, efficacy study for their lead drug candidate ATB-346.   The study will run in Canada and is expected to conclude in December 2018.

Read More